Device Trial Radar · NCT07950436
Esprit BTK Japan Post-Marketing Surveillance
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Actual
Start
Oct 3, 2025
Primary completion
Aug 25, 2027
Study completion Sep 19, 2031
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Esprit BTK Japan Post-Marketing Surveillance (PMS) is a database-based PMS. The purpose of this PMS is to confirm the safety and effectiveness of the Esprit BTK Everolimus Eluting Resorbable Scaffold System for the treatment of below-the-knee artery disease in the real-world clinical setting in Japan. The Surveillance will register all patients in whom treatment with Esprit BTK was attempted.
Conditions
- Chronic Limb-Threatening Ischemia
Interventions
Esprit BTK Everolimus Eluting Resorbable Scaffold SystemDevice
The Esprit BTK implant procedure is as follows: 1. If any inflow artery (non-target vessel) needs to be treated, it will be first treated before implanting Esprit BTK 2. If more than one stenosed and/or occlusive arteries were observed, the lesion(s) in the artery which is suspected to be "culprit" will be treated with Esprit BTK, if possible, as the target lesion(s). 3. If any IP lesion needs to be treated without using Esprit BTK, it will be first treated as a non-target lesion before implanting Esprit BTK. 4. Target lesions will be pre-dilated. 5. Esprit BTK will be implanted only when the target lesion is successfully predilated as determined by the operator. 6. Esprit BTK will be implanted according to the IFU and the proper device use policy established by CVIT and associated professional societies. The entire pre-dilated segment should be covered with scaffold(s). 7. After successful Esprit BTK implantation, the target lesion will be post-dilated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from Major Adverse Limb Event (MALE) + Peri-Operative Death (POD)Time frame: 6 Months
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Osaka Police Hospital
Osaka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.